Arterial Elasticity Screening in Preventive Cardiology

Abstract

Arterial elasticity, a key marker of vascular health, has emerged as an important focus in preventive cardiology. Loss of arterial elasticity precedes overt cardiovascular disease, providing an opportunity for early risk stratification and intervention. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, and management strategies related to arterial stiffness. It further explores recent advances, including novel screening techniques and emerging therapies, and summarizes guideline-based recommendations for clinical practice. The integration of arterial elasticity screening into preventive cardiology could enhance early detection, guide individualized management, and ultimately reduce cardiovascular morbidity and mortality.

Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, despite decades of advances in diagnosis and therapy. Traditional risk assessment models, while helpful, often fail to identify subclinical vascular changes that precede clinical events. Arterial elasticity, reflecting the ability of arteries to expand and contract with cardiac pulsation and blood flow, has emerged as a robust surrogate marker for vascular aging and early atherosclerotic change. Early identification of decreased arterial elasticity could facilitate timely interventions, improve risk stratification, and enhance preventive strategies in clinical cardiology.

Epidemiology / Disease Burden

Globally, the prevalence of reduced arterial elasticity increases with age, affecting up to 80% of adults over 65 years. Epidemiological studies, such as the Framingham Heart Study and Multi-Ethnic Study of Atherosclerosis (MESA), have demonstrated a strong association between arterial stiffness and incident CVD, including coronary artery disease, stroke, and heart failure. Populations with hypertension, diabetes, chronic kidney disease, and metabolic syndrome exhibit accelerated vascular stiffening, amplifying their risk. The burden is particularly significant in regions with high prevalence of lifestyle-related risk factors and limited access to preventive care.

Pathophysiology

Arterial elasticity is governed by the structural and functional integrity of the arterial wall, particularly the balance between elastin and collagen fibers in the medial layer. With advancing age and exposure to risk factors, elastin degrades and is replaced by stiffer collagen, leading to increased arterial stiffness. Endothelial dysfunction, inflammation, oxidative stress, and vascular smooth muscle cell remodeling further contribute to this process. Hemodynamic consequences include increased systolic blood pressure, widened pulse pressure, left ventricular hypertrophy, and compromised coronary perfusion, all of which promote target organ damage.

Risk Factors

Multiple modifiable and non-modifiable risk factors accelerate arterial stiffening. Key contributors include advancing age, hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, obesity, physical inactivity, and smoking. Genetic predisposition also plays a role, as do racial and ethnic differences. Emerging evidence suggests that early-life exposures, such as childhood obesity and low birth weight, may have lasting effects on vascular elasticity. Identification and modification of these risk factors remain central to prevention strategies.

Clinical Features

Reduced arterial elasticity is typically asymptomatic in early stages, underscoring the importance of screening. Clinically, patients may present with isolated systolic hypertension, widened pulse pressure, or signs of target organ damage such as left ventricular hypertrophy, microalbuminuria, or cognitive decline. In advanced cases, complications of cardiovascular disease including myocardial infarction, stroke, and heart failure may ensue. Assessment of arterial elasticity can therefore provide valuable prognostic information well before the onset of clinical symptoms.

Diagnosis

Non-invasive assessment of arterial elasticity has become increasingly feasible in clinical practice. Carotid-femoral pulse wave velocity (cfPWV) is considered the gold standard, providing reproducible and robust measures of central arterial stiffness. Other modalities include brachial-ankle PWV, augmentation index, and oscillometric pulse contour analysis. Emerging techniques, such as 4D flow MRI and arterial compliance imaging, offer additional insights into regional vascular properties. Interpretation of findings should incorporate age- and sex-specific reference values and consider confounding factors such as heart rate and blood pressure at the time of measurement.

Treatment & Management

Management of reduced arterial elasticity hinges on aggressive control of modifiable risk factors. Antihypertensive agents, particularly those targeting the renin-angiotensin-aldosterone system (RAAS), have demonstrated efficacy in reducing arterial stiffness. Statins, glucose-lowering agents, and weight reduction also contribute to improved vascular compliance. Lifestyle modification, including regular aerobic exercise, dietary sodium restriction, smoking cessation, and moderation of alcohol intake, is foundational. In select populations, individualized pharmacotherapy guided by arterial function measurements may further optimize outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in both screening and therapeutic interventions. Portable and automated devices now enable rapid, point-of-care assessment of arterial stiffness, facilitating broader implementation in clinical and community settings. Novel pharmacologic agents, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists, have shown promise in improving arterial compliance beyond their primary indications. Research into regenerative therapies, including stem cell and gene-based approaches targeting elastin repair, is ongoing. Artificial intelligence (AI)-driven algorithms are being developed to enhance prediction and personalization of preventive strategies based on arterial function data.

Guideline Recommendations

Major cardiovascular societies, including the European Society of Cardiology (ESC) and American Heart Association (AHA), recognize arterial stiffness as an independent predictor of cardiovascular risk. ESC guidelines advocate for the use of cfPWV in selected patients, particularly those at intermediate risk, to refine risk stratification and guide management. The AHA highlights the value of integrating arterial function assessment into comprehensive cardiovascular risk evaluation, especially in patients with multiple comorbidities. Ongoing refinement of guideline recommendations is expected as evidence continues to mount regarding the utility and practicality of widespread arterial elasticity screening.

Conclusion

Arterial elasticity screening represents a pivotal advancement in preventive cardiology, offering a window into subclinical vascular disease and new opportunities for early intervention. Robust evidence supports its prognostic value and feasibility in diverse clinical settings. As technology advances and evidence accumulates, routine assessment of arterial stiffness is likely to become integral to personalized cardiovascular risk management. Continued research, education, and collaboration are essential to harness the full potential of arterial elasticity screening in reducing the global burden of cardiovascular disease.